109 related articles for article (PubMed ID: 27145392)
1. [Grave diarrhea associated with idelalisib administration].
Suárez Del Olmo D; Corregidor Luna L; Hidalgo Correas FJ; García Benayas E; García Díaz B
Farm Hosp; 2016 May; 40(3):227-9. PubMed ID: 27145392
[No Abstract] [Full Text] [Related]
2. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib for chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
[No Abstract] [Full Text] [Related]
4. Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
Weidner AS; Panarelli NC; Geyer JT; Bhavsar EB; Furman RR; Leonard JP; Jessurun J; Yantiss RK
Am J Surg Pathol; 2015 Dec; 39(12):1661-7. PubMed ID: 26448188
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
Louie CY; DiMaio MA; Matsukuma KE; Coutre SE; Berry GJ; Longacre TA
Am J Surg Pathol; 2015 Dec; 39(12):1653-60. PubMed ID: 26426383
[TBL] [Abstract][Full Text] [Related]
6. Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
[TBL] [Abstract][Full Text] [Related]
7. PI3K-δ inhibitor produces long-lasting responses.
Cancer Discov; 2013 Jul; 3(7):OF11. PubMed ID: 23847354
[TBL] [Abstract][Full Text] [Related]
8. [Polymicrobial lung infection associated with idelalisib administration].
Rodríguez-Ferreras A; Velasco-Roces L; Lázaro-López E; Zapico-García I
Farm Hosp; 2018 Jan; 42(1):25-26. PubMed ID: 29306311
[No Abstract] [Full Text] [Related]
9. Abdominal Pain and Bloody Diarrhea.
Gupta A; Peng L; Li HC
JAMA Oncol; 2016 Oct; 2(10):1361-1362. PubMed ID: 27442133
[No Abstract] [Full Text] [Related]
10. Idelalisib in the management of lymphoma.
Cheah CY; Fowler NH
Blood; 2016 Jul; 128(3):331-6. PubMed ID: 27252232
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib: deaths from infections. Toxicity and doubtful efficacy.
Prescrire Int; 2016 Oct; 25(175):243. PubMed ID: 30688423
[No Abstract] [Full Text] [Related]
12. Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia.
Lafon-Desmurs B; Monsel G; Leblond V; Papo M; Caumes E; Fekkar A; Jaureguiberry S
Med Mal Infect; 2017 Jun; 47(4):293-296. PubMed ID: 27818019
[No Abstract] [Full Text] [Related]
13. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
Shiver MB; Mahmoud F; Gao L
N Engl J Med; 2015 Oct; 373(16):1580-2. PubMed ID: 26466009
[No Abstract] [Full Text] [Related]
14. Idelalisib: targeting PI3Kδ in B-cell malignancies.
Gilbert JA
Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809089
[No Abstract] [Full Text] [Related]
15. Idelalisib induced CMV gastrointestinal disease: the need for vigilance with novel therapies.
Goldring L; Kumar B; Gan TE; Low MSY
Pathology; 2017 Aug; 49(5):555-557. PubMed ID: 28693750
[No Abstract] [Full Text] [Related]
16. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Curigliano G; Shah RR
Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
[TBL] [Abstract][Full Text] [Related]
17. Discussion: Managing Risk When Using Idelalisib.
Coutre SE; Burger JA; Pagel JM
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):13. PubMed ID: 27168205
[No Abstract] [Full Text] [Related]
18. Multiple mucosal ulcerations caused by idelalisib.
Galeone M; Antiga E
Int J Dermatol; 2017 Sep; 56(9):e180-e181. PubMed ID: 28244069
[No Abstract] [Full Text] [Related]
19. Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
Hammami MB; Al-Taee A; Meeks M; Fesler M; Hurley MY; Cao D; Lai JP
Clin J Gastroenterol; 2017 Apr; 10(2):142-146. PubMed ID: 28025783
[TBL] [Abstract][Full Text] [Related]
20. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Hanlon A; Brander DM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
